JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2004; 44:2339-2348, doi:10.1016/j.jacc.2004.09.041
© 2004 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guazzi, M.
Right arrow Articles by Guazzi, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guazzi, M.
Right arrow Articles by Guazzi, M. D.

The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure

Marco Guazzi, MD, PhD, FACC*,*, Gabriele Tumminello, MD*, Fabio Di Marco, MD{dagger}, Cesare Fiorentini, MD* and Maurizio D. Guazzi, MD, PhD{ddagger}

* Cardiopulmonary Laboratory, Cardiology Division, University of Milano, San Paolo Hospital, Milan, Italy
{dagger} Respiratory Unit, University of Milano, San Paolo Hospital, Milan, Italy
{ddagger} Institute of Cardiology, University of Milano, Milan, Italy



View larger version (28K):

[in a new window]
  		Figure 1 Cardiopulmonary exercising testing measurements (A, oxygen uptake [VO2] kinetics; B, slope of increase in ventilation versus carbon dioxide production [VE/VCO2 slope]; and C, rate of oxygen uptake increase per work rate [{Delta}VO2/{Delta}WR]) of one patient with moderate congestive heart failure secondary to ischemic cardiomyopathy (age 60 years, left ventricular ejection fraction of 34%, and systolic pulmonary pressure of 38 mm Hg) recorded after placebo and after sildenafil intake. Protocol consisted of 2 min of rest, 2 min of unloaded exercise at 60 rpm (Unl. Exe. ), ramp work rate of 15 W · min–1 to maximal exercise tolerance, and 6 min of recovery. Oxygen uptake kinetics data were computer-collected as breath-by-breath measurements, interpolated second-by-second, and averaged at 10-s intervals; VE/VCO2 incremental changes during maximal exercise data are plotted at 20-s intervals; {Delta}VO2/{Delta}WR incremental changes during maximal exercise data are plotted at 20-s intervals.

 


View larger version (13K):

[in a new window]
  		Figure 2 Correlations of changes, after sildenafil, in lung diffusing capacity for carbon monoxide (DLco) versus brachial artery reactive hyperemia and changes in slope of increase in ventilation versus carbon dioxide output (VE/VCO2 slope) versus rate of oxygen uptake increase per work rate ({Delta}VO2/{Delta}WR) in patients with chronic heart failure.

 


View larger version (25K):

[in a new window]
  		Figure 3 Correlations of changes in rate of oxygen uptake increase per work rate ({Delta}VO2/{Delta}WR) versus tau recovery and brachial artery hyperemia versus tau recovery, at baseline and after sildenafil, in patients with chronic heart failure.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2004 by the American College of Cardiology Foundation.